Mindfulness meditation in the treatment of substance use disorders and preventing future relapse: neurocognitive mechanisms and clinical implications
dc.contributor.author | Priddy, Sarah E. | |
dc.contributor.author | Howard, Matthew O. | |
dc.contributor.author | Hanley, Adam W. | |
dc.contributor.author | Riquino, Michael R. | |
dc.contributor.author | Friberg-Felsted, Katarina | |
dc.contributor.author | Garland, Eric L. | |
dc.date.accessioned | 2019-09-18T15:01:12Z | |
dc.date.available | 2019-09-18T15:01:12Z | |
dc.date.issued | 2018-11-16 | |
dc.identifier.citation | Priddy, S.E., Howard, M.O., Hanley, A.W., Riquino, M.R., Friberg-Felsted, K., & Garland, E.L. (2018). Mindfulness meditation in the treatment of substance use disorders and preventing future relapse: Neurocognitive mechanisms and clinical implications. Substance Abuse and Rehabilitation, 9, 103-114. doi: 10.2147/SAR.S145201 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/29602 | |
dc.description.abstract | Substance use disorders (SUDs) are a pervasive public health problem with deleterious consequences for individuals, families, and society. Furthermore, SUD intervention is complicated by the continuous possibility of relapse. Despite decades of research, SUD relapse rates remain high, underscoring the need for more effective treatments. Scientific findings indicate that SUDs are driven by dysregulation of neural processes underlying reward learning and executive functioning. Emerging evidence suggests that mindfulness training can target these neurocognitive mechanisms to produce significant therapeutic effects on SUDs and prevent relapse. The purpose of this manuscript is to review the cognitive, affective, and neural mechanisms underlying the effects of mindfulness-based interventions (MBIs) on SUDs. We discuss the etiology of addiction and neurocognitive processes related to the development and maintenance of SUDs. We then explore evidence supporting use of MBIs for intervening in SUDs and preventing relapse. Finally, we provide clinical recommendations about how these therapeutic mechanisms might be applied to intervening in SUDs and preventing relapse. | en_US |
dc.description.sponsorship | National Institute of Health (NIH) award to ELG (R01DA042033) | en_US |
dc.publisher | Dove Medical Press | en_US |
dc.rights | © 2018 Priddy et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. https://www.dovepress.com/terms.php | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/3.0/ | en_US |
dc.subject | Addiction | en_US |
dc.subject | Mindfulness | en_US |
dc.subject | Reward | en_US |
dc.subject | Relapse | en_US |
dc.subject | Substance use disorders | en_US |
dc.title | Mindfulness meditation in the treatment of substance use disorders and preventing future relapse: neurocognitive mechanisms and clinical implications | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Riquino, Michael R. | |
kusw.kudepartment | Social Welfare | en_US |
kusw.oanotes | Per SHERPA/RoMEO, 2019-09-18: Author's Pre-print: cross author cannot archive pre-print (ie pre-refereeing) Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing) Publisher's Version/PDF: green tick author can archive publisher's version/PDF General Conditions: On institutional repository, central repository or subject -based repository, including PubMed Central Creative Commons Attribution Non-Commercial License UK funded authors may use a Creative Commons Attribution License On a non-profit server Must link to publisher version Published source (journal and Dove Medical Press) must be acknowledged as original place of publication Publisher's version/PDF may be used | en_US |
dc.identifier.doi | 10.2147/SAR.S145201 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0001-5052-541X | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-0373-2421 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess | en_US |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: © 2018 Priddy et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. https://www.dovepress.com/terms.php